Kornimate/medical-research-clean huggingface dataset:
preliminary study of sonic hedgehog signaling pathway in the pathogenesis of rheumatoid arthritis

Conditions: Arthritis, Rheumatoid; Neovascularization, Pathologic; Synovitis

Summary: rheumatoid arthritis(ra) with a high incidence and high morbidity, the pathogenesis has not been fully elucidated. fibroblast-like synovial cells excessive proliferation and synovial angiogenesis is the most important cause of ra synovitis and joint destruction. our study was to find the role of sonic hedgehog(shh) pathway in regulating proliferation of fibroblast-like synovial cells and modulating excess angiogenesis of synovial tissue.

4ml blood from active ra patients(n=35) and healthy volunteers (n=35) will be collected * peripheral blood mononuclear cells will be detached * messenger ribonucleic acid expression of sonic hedgehog pathway associated factors in both groups will be detected synovial tissues from 4 ra patients and 4 patients with traumatic or meniscal injury who need to carry out knee joint replacement operation will be collected * inflammatory feature of synovial tissue will be observed * the expression of shh, ptch1, gli1 and smo in synovial tissue will be detected by immunohistochemistry assay * fibroblast-like synoviocytes will be cultured from synovial tissue of ra patients

Eligibility criteria:
inclusion criteria: * definitely diagnosed * the disease is active (das28\>3.2) exclusion criteria: * combined with severe organ dysfunction * combined with other rheumatic diseases

Keywords: arthritis, rheumatoid sonic hedgehog protein, human neovascularization, pathologic synovitis
pediatric hypothalamic obesity

Conditions: Obesity

Summary: this trial is being conducted in pediatric patients with hypothalamic obesity. this generally occurs in people who have had an injury to or tumor in their hypothalamus (gland or organ that secretes hormones). the purpose of this trial is to see how an investigational treatment controls the hormone insulin by lowering the level of insulin in the body resulting in a weight loss in children who are at least 6 years of age but less than 18 years of age. some children in this trial will receive placebo. to qualify for this study, you and your child's doctor must feel that your child's weight is inadequately controlled within a year from the time of injury to the hypothalamus or tumor of the hypothalamus. this study will help to determine if an investigational treatment is of benefit in controlling a child's weight.


Eligibility criteria:
* male and female patients ages 6 to less than 18 * patients who have experienced any form of cranial insult related to cranial trauma, or to a tumor or it's treatment (i.e. surgery, radiation, and/or chemotherapy) * patients who are at least one year out following therapy for their tumor * patients who have severe cardiovascular dysfunction (for example cardiomyopathy, congestive heart failure (nyha class iii or iv), unstable angina, sustained ventricular tachycardia, ventricular fibrillation) will be excluded * patients with severe neurologic handicaps which preclude normal physical activity will be excluded. * patients confined to bed and those patients who are wheelchair bound which prevents them from activities of daily living or normal physical activity, i.e. walking, will be excluded from the trial * your child must be greater than 120% of their ideal body weight for their height or have a body mass index that is greater than or equal to 27.
the relevance between the level of fetal hemoglobin and short-term complications in extremely preterm infants

Conditions: Fetal Hemoglobin

Summary: a monocentric prospective study was conducted to find the relevance between the level of fetal hemoglobin and short-term complications in extremely preterm infants


Eligibility criteria:
inclusion criteria: 1. preterm infants with gestational age \<32 weeks or birth weight \<1500g 2. parents agree to attend exclusion criteria: 1. serious functional or organic diseases 2. severe congenital deformity 3. parents reject to attend
a randomized clinical trial on hemoglobin dose and patient matching

Conditions: Anemia

Summary: the aim of this study is to evaluate whether the targeted hemoglobin increment (2 grams per decilitre) in the patient can be predicted from the hemoglobin dose/weight of the blood bag transfused. in the test group, the hemoglobin dose needed will be calculated, whereas in the control group, the prescribed number of red cell units will be transfused. hypothesis: by matching the hemoglobin dose to the individual needs of the patient the investigators will reduce the total usage of red cell concentrates.

this is a randomized clinical study on hemoglobin dose and patient matching. the aim of the study is to evaluate whether the targeted hemoglobin increment (2 grams per decilitre) in the patient can be predicted from the hemoglobin dose/weight of the blood bag transfused. in the test group, the hemoglobin dose needed will be calculated, whereas in the control group, the prescribed number of red cell units will be transfused.

Eligibility criteria:
inclusion criteria: * patients receiving red cell transfusions or expected to receive one or more red cell transfusions * patients over 16 years of age * patients for whom height and weight information is available * patients who have consented to participate exclusion criteria: * patients who are hemodynamically unstable (ongoing bleeding or hemolysis) * patients with a known hemolytic anemia (congenital or acquired) * patients with a positive direct antiglobulin test (dat) * patients for whom informed consent has not been obtained * patients where the hemoglobin concentration increment target is above 2g/dl. * patients with auto- or alloantibodies against rbcs (red blood cells)..

Keywords: hemoglobins
vaccination by leukemic apoptotic corpse autologous pulsed dendritic cells for acute myelogenous leukemia (aml) patients in first or second complete remission (cr)(cd lam)

Conditions: Acute Myelogenous Leukemia

Summary: dendritic cells vaccinations are increasingly used in order to develop antitumoral immune response. this will be a phase 2 trial using autologous dendritic cells pulsed with leukemic apoptotic corpse in acute myelogenous leukemia (aml) patients in first or second complete remission (cr).


Eligibility criteria:
inclusion criteria: * age ≥ 60 years * informed consent signed * serology hiv, hepatitis b, hepatitis c, htlv 1 and 2 and syphilis always negative (new achievement tests) * performance statute \<=2 * must not be eligible for allogeneic transplantation * no progressive disease * bone marrow and/or peripheral blasts \>50% before chemotherapyblasts \>=2.4 10\*8 (collected prior to chemotherapy) available no contraindication to cytapheresis * aml in cr2, except m3-aml * patients with refractory aml after induction treatment and a patient eligible for salvage treatment may allow the production of a first complete remission. * patient with newly diagnosed aml with unfavorable cytogenetics and for whom (which) a course of intensive induction and consolidation treatment for outpatients are possible * patient with newly diagnosed aml with a non-adverse cytogenetics and either refused to participate in the protocol goelams lams-2007, against the exclusion criteria, indicating participation in the protocol goelams lams-2007 and for whom (which) a course of induction and intensive out patient treatment for consolidation are possible * absence of donor hla-compatible family or non-family and absence of placental blood available for performing an allograft. exclusion criteria * patients who, for reasons psychological, social or geographical boundaries, could be monitored during the study * no infections or visceral (cardiac, lung, brain, ...) serious uncontrolled * history of positive allogeneic bone marrow or solid organ transplantation. * previous history of autoimmune disease other than vitiligo * history of other cancer, except cervical carcinoma in situ or basal cell carcinoma of the skin unless deemed cured for over 5 years. * inability to collect at the diagnosis of relapsed aml, enough leukemic cells (\> 2.4 x108) * inability to collect during remission, a sufficient number of monocytes in two leukapheresis maximum * failure to obtain a maturation of monocytes * patient with aml 3 * patient may receive an allogeneic hematopoietic stem cell * no treatment related to treatment of molecules in preclinical development underway or completed ma within the last 4 weeks

Keywords: antitumoral immune response after autologous dendritic cells vaccination
electrical resynchronization and acute hemodynamic effects of direct his bundle pacing compared to biventricular pacing

Conditions: Cardiac Pacing, Artificial; Cardiac Resynchronization Therapy; Direct His Bundle Pacing

Summary: the aims are to compare direct his bundle pacing (dhbp) with biventricular pacing (biv) in terms of electrical resynchronization using electrocardiographic imaging (ecgi) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. the study will be a randomized crossover design with acute measurements.

by recruiting native conducting tissue to relay electrical activation of the ventricles via the purkinje fibre network, dhbp may potentially achieve greater electrical resynchronization and hemodynamic benefit compared to biv where the electrical activation wavefronts propagate from two discrete pacing sites. electrical synchrony achieved by these pacing modes have however never been compared. furthermore, the acute hemodynamic effect of dhbp has been compared to biv only in a small single study to date. the aims are to compare dhbp with biv in terms of electrical resynchronization using electrocardiographic imaging (ecgi) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. the primary endpoint will be left ventricular activation time, with secondary endpoints including various electrical (right ventricular activation time, total ventricular activation time etc) and hemodynamic parameters (systolic pressure, cardiac output, cardiac contractility). it is expected that dhbp offers shorter left ventricular activation time (i.e. better synchrony) and hemodynamic benefit compared to biv.

Eligibility criteria:
inclusion criteria: * treatment of heart failure with a standard indication for crt (nyha iii-iv, lvef \ 130ms; or lvef\< 40% and requirement for frequent ventricular pacing, irrespective of baseline qrs duration) and optimal medical treatment. * permanent atrial fibrillation (allowing connection of the dhbp lead to the atrial port). * patients implanted with 1) a crt pacemaker or crt defibrillator 2) a his lead with selective or non-selective dhbp, connected to the atrial port of the generator 3) a functional right ventricular lead and 4) a functional coronary sinus lead. * dhbp with selective or non-selective his capture exclusion criteria: * age \<18 years * pregnancy * inability to undergo ct or an mri (e.g. due to severe claustrophobia) * inability or refusal to sign the patient informed consent form.
clinicopathological importance of colorectal medullary carcinoma: retrospective cohort study

Conditions: Colorectal Medullary Carcinoma

Summary: medullary carcinoma (mc) is a rare tumor with solid growth pattern without glandular differentiation and constitute less than 1% of colorectal cancer. lymph node positivity and distant organ metastasis were reported to be lower than other poorly differentiated adenocarcinomas. therefore, the diagnosis of mc is pathologically important in terms of follow-up and treatment. mc is commonly localized in the right colon, has a large tumor size, and is mostly diagnosed in the t4 stage. as mc most likely have defects in dna mmr, the correct pathological diagnosis is important for the postoperative treatment and the prognosis of the patients.

427 patients with colorectal cancer who were underwent surgery between january 2011 and december 2017, were evaluated retrospectively into 2 groups as mc (n:13) and non-mc (n:414) in terms of demographic characteristics, pathological data and oncological outcomes.

Eligibility criteria:
inclusion criteria: * colorectal cancer diagnosis, medullary carcinoma exclusion criteria: * none

Keywords: medullary carcinoma colorectal cancer microsatellite instability
phase iv clinical trial of an influenza split vaccine anflu

Conditions: Influenza

Summary: to evaluate the safety and immunogenicity of the three consecutive lots of an seasonal split influenza vaccine anflu in adults, a randomized, double-blind and controlled clinical trial was conducted in 560 subjects in tianjin city of china.


Eligibility criteria:
inclusion criteria: * healthy adults aged 18-60 years old * be able to show legal identity card for the sake of recruitment without vaccination history of seasonal split influenza vaccine in the recent 3 years * not participate in any other clinical trials during the study * not receive any immunosuppressive agents during and one month prior to the study * be able to understand and sign the informed consent. exclusion criteria: * woman： who breast-feeding or planning to become pregnant during the study * any history of allergic reactions; was allergic to any component of the vaccine, such as eggs or ovalbumin * any history of severe adverse reactions to vaccines, such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain * autoimmune disease or immunodeficiency * acute episode of chronic diseases or conditions, including chronic hepatitis, hypertension, diabetes mellitus and cardiovascular diseases * guillain-barre syndrome * women subjects with positive urinary pregnancy test * any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis) * axillary temperature \>37.0 centigrade at the time of dosing * psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment * any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.
agn-229666 ophthalmic solution for the treatment of seasonal or perennial allergic conjunctivitis

Conditions: Conjunctivitis, Allergic

Summary: this study will evaluate the safety and efficacy of agn-229666 for the treatment of seasonal or perennial allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * japanese patients living in japan with allergic conjunctivitis with itching and redness * able and willing to discontinue wearing any contact lenses during the study period. exclusion criteria: * eye surgical intervention and/or a history of refractive surgery within 6 months * history of retinal detachment, diabetic retinopathy, or progressive retinal disease * presence of active eye infection (bacterial, viral, or fungal) * history of an eye herpetic infection * use of corticosteroids within 6 months or anticipated use during the study.
study investigating the safety and efficacy of hp802-247 in the treatment of venous leg ulcers >12 cm2 to ≤ 36 cm2

Conditions: Venous Leg Ulcers

Summary: this study is being done to find out if an investigational product called hp802-247 can help people with venous leg ulcers. investigational means that hp802-247 has not been approved by the u.s. food and drug administration (fda). at least 250 subjects will participate. the study is going to be conducted in approximately 50 sites in the united states and canada.

this research is being done to compare the efficacy of hp802-247 plus compression therapy against vehicle plus compression therapy in achieving complete wound closure over the 16-week treatment period. vehicle looks the same as hp802-247 but contains no cells. target wound status is evaluated at each study visit (closed, open, reopened). at wound closure or completion of treatment all subject will enter an observational safety followed up period which ends at one year after initial exposure to test article.

Eligibility criteria:
inclusion criteria: * provide informed consent. * age ≥ 18 years and of either sex. * willing to comply with protocol instructions, including allowing all study assessments. * have a venous leg ulcer (vlu) between the knee and ankle (at or above the malleolus), with a surface area \>12 cm2 to ≤ 36 cm2 * venous insufficiency confirmed by duplex doppler ultrasound examination for valvular or venous incompetence. * arterial supply adequacy confirmed * target ulcer involves a full thickness skin loss, but without exposure of tendon, muscle, or bone. * target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months). * acceptable state of health and nutrition exclusion criteria: * history of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin b. * prior diagnosis of systemic lupus erythematosus with elevated anti-dna antibody titers, buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication. * therapy with another investigational agent within thirty (30) days of screening, or during the study. * a target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic). * documented history of osteomyelitis at the target wound location within 6 months preceding the screening visit. * refusal of or inability to tolerate compression therapy. * therapy of the target ulcer with autologous skin graft, apligraf™, or dermagraft™ within 30 days preceding the screening visit. * history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers). * any prior exposure to hp802-247 or its vehicle.

Keywords: venous leg ulcer ulcer venous stasis compression venous venous stasis ulcer vlu wound varicose veins venous insufficiency dvt deep vein thrombosis
role of opioids in epidural solutions

Conditions: Postoperative Pain

Summary: it is unclear whether addition of opioids to epidural solutions for postoperative analgesia is beneficial. in this multicenter randomized double-blinded trial, we aim to test the primary hypothesis that epidural solutions containing only bupivacaine are as effective as solutions containing both bupivacaine and fentanyl in promoting analgesia in patients recovering from open abdominal surgery. we also aim to assess the incidence of epidural-induced hypotension, the difference in patient-reported opioid side-effects between the two groups. if we demonstrate no clinically important difference between the two interventions, clinicians will be able to substantially reduce the amount of opioids patients receive during their postoperative recovery, and potentially decrease the associated high incidence of opioid adverse effects in post-surgical patients.


Eligibility criteria:
inclusion criteria: 1. written informed consent 2. 18-85 years old 3. undergoing open abdominal surgery (including colorectal, intestinal, gastric, pancreatic, hepatobiliary, urological, or gynecological surgery) 4. for which a clinical decision has been made to provide epidural analgesia preoperatively and extending to the post-operative period 5. anticipated hospitalization of at least 2 nights exclusion criteria: 1. known allergy to bupivacaine or fentanyl 2. chronic liver disease, defined as cirrhosis, portal hypertension, or variceal bleeding 3. patients under chronic alpha-blocking agents for hypertension 4. clinical contraindications to epidural introduction, as judged by the anesthesia provider (thrombocytopenia, un-interrupted anticoagulation, clinically-significant atrio-ventricular conduction block, etc.) 5. pregnant women
a combination therapy in patients with social anxiety disorder

Conditions: Social Phobia

Summary: the purpose of this study is to assess the efficacy, safety and tolerability of a combination of vestipitant and paroxetine in patients with social anxiety disorder (sad)


Eligibility criteria:
inclusion criteria: * primary diagnosis of generalised social anxiety disorder as defined in dsm-iv. * capable of giving informed consent and willing to comply with the study requirements. * women of childbearing potential must agree to one of a number of defined acceptable methods of birth control. exclusion criteria: * primary diagnosis within the past 6 months of another axis 1 disorder such as major depression or another anxiety disorder. * use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type. * subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. * subjects who currently meet or who met within 6 months prior to screening dsm-iv criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening dsm-iv criteria for substance dependence (other than nicotine). * significantly abnormal blood or urine laboratory tests or electrocardiogram (ecg).

Keywords: anxiety social anxiety disorder sad